Neck Dissection Part 1

8/2/2019 Neck Dissection Part 1

1/30

Pocket Guide To

TNM STAGING OF HEADAND NECK CANCERAND NECK DISSECTION

CLASSIFICATION

Edited byDaniel G. Deschler, MD

Terry Day, MD

AAOHNS/F American Head andNeck Society


2/30


3/30

1

Pocket Guide to

NECK DISSECTIONCLASSIFICATION AND TNM

STAGING OF HEAD ANDNECK CANCER

Committee for Head and Neck Surgeryand Oncology

American Academy of OtolaryngologyHead and Neck Surgery

Neck Dissection Classification CommitteeAmerican Head and Neck Society

Edited byDaniel G. Deschler, MDTerry Day, MD

Primary ContributorsAnand K. Sharma, MD

Merrill S. Kies, MD

__________

Published byAmerican Academy of Otolaryngology

Head and Neck Surgery Foundation, Inc.

One Prince Street, Alexandria, VA 22314-3357


4/30

2

First Edition 1991K. Thomas Robbins, MD; editor

Second Edition 2001K. Thomas Robbins, MD; editor

Third Edition 2008

Library of Congress Cataloging-in-Publication DataPocket guide to neck dissection classification and TNM staging of head andneck cancer. 3rd ed. / Committee for Head and Neck Surgery and Oncol-ogy, American Academy of OtolaryngologyHead and Neck Surgery [and]Neck Dissection Classification Committee, American Head and Neck Soci-ety; edited by Daniel G. Deschler, Terry Day ; primary contributors, AnandK. Sharma, Merrill S. Kies.

p. ; cm.Rev. ed. of: Pocket guide to neck dissection classification and TNM

staging of head and neck cancer / Committee for Neck DissectionClassification, American Head and Neck Society [and] Committee for Headand Neck Surgery and Oncology, American Academy of OtolaryngologyHead and Neck Surgery ; edited by K. Thomas Robbins. 2nd ed. 2001.

Includes bibliographical references.ISBN 978-1-56772-117-1 (pbk.)

1. NeckSurgeryClassificationHandbooks, manuals, etc. 2. NeckTumorsClassificationHandbooks, manuals, etc. 3. NeckLymphaticsHandbooks, manuals, etc. 4. HeadTumorsClassificationHandbooks,manuals, etc. I. Deschler, Daniel G. II. Day, Terry A. III. Sharma, Anand K.IV. Kies, Merrill S. V. American Academy of OtolaryngologyHead andNeck Surgery. Committee for Head and Neck Surgery and Oncology. VI.American Head and Neck Society. Neck Dissection Classification Commit-tee. VII. American Academy of OtolaryngologyHead and Neck Surgery

Foundation.[DNLM: 1. Neck DissectionclassificationHandbooks. 2. Head and

Neck NeoplasmssurgeryHandbooks. 3. Neoplasm Stagingclassifica-tionHandbooks. WE 39 P739 2008]

RC280.N35P63 2008616.99'491dc22

2008022331


5/30

3

AMERICAN ACADEMY OF OTOLARYNGOLOGYHEAD AND NECK SURGERY

HEAD AND NECK SURGERY COMMITTEE

FACULTY

DEVRAJ BASU, MD PhD

ERIC T. BECKEN, MD

JOSEPH BRENNAN, MD

MARION E. COUCH, MD PHD

DANIEL G. DESCHLER, MDDAVID W. EISELE, MD

CHRISTINE G. GOURIN, MD

PATRICK JOSEPH GULLANE, MD FRCS(C)

STEPHEN Y. LAI, MD PhD

WILLIAM P. MAGDYCZ, MD

KELLY MICHELE MALLOY, MD

JAMES P. MALONE MD

ABBY C. MEYER, MD

CHERIE ANN O. NATHAN MD

BRIAN NUSSENBAUM, MD

URJEET PATEL, MD

CECELIA E. SCHMALBACH, MD

THEODOROS N. TEKNOS, MDMARILENE B. WANG, MD

WENDELL G. YARBROUGH, MD

BEVAN YUEH, MD MPH

With appreciation to all former committee

members who contributed.


6/30

4

NECK DISSECTION CLASSIFICATION COMMITTEE

AMERICAN HEAD AND NECK SOCIETY

K. Thomas Robbins, MD (Chair)

Joseph A. Califano, MD

Gary L. Clayman, MD, DDS

Jesus E. Medina, MD

Ashok R. Shaha, MD

Peter M. Som, MD

Gregory T. Wolf, MD

Alfio Ferlito, MD


7/30

5


8/30

6

ACKNOWLEDGMENTS

The American Head and Neck Society Committee acknowledgesthe input from the Head and Neck Surgery and Oncology Commit-tee and the Head and Neck Surgery Education Committee of theAmerican Academy of OtolaryngologyHead and Neck Surgery,and the Council of the American Head and Neck Society. Appre-ciation is also extended to Douglas Denys, MD, for the illustrationsand the AJCC for the use of staging information from the 6th edi-tion of the AJCC Cancer Stating Manual.

This monograph has been endorsed by the American Head and

Neck Society and The American Academy of OtolaryngologyHead and Neck Surgery.


9/30

7

TABLE OF CONTENTSI. Introduction .............................................................................8

A. Upper Aerodigestive Tract Sites ...........................................81. Oral Cavity .....................................................................9

2. Oropharynx ....................................................................93. Hypopharynx................................................................104. Larynx...........................................................................115. Nasopharynx ................................................................126. Nasal Cavity and Paranasal Sinuses ..............................13

B. Radiation Therapy and Chemotherapy...............................14

II. American Joint Committee on Cancer (AJCC) Tumor

Staging by Site........................................................................16A. Oral Cavity ........................................................................16B. Oropharynx .......................................................................16C. Larynx ...............................................................................17D. Hypopharynx.....................................................................19E. Nasal Cavity and Paranasal Sinuses ...................................20F. Salivary Glands..................................................................21G. Neck Staging Under the TNM Staging System for Head

and Neck Tumors (excluding nasopharynx and thyroid).....22H. TNM Staging for the Larynx, Oropharynx, Hypopharynx,

Oral Cavity, Salivary Glands, and Paranasal Sinuses ..........23

III. AJCC Tumor StagingNasopharynx and Thyroid...................24A. Nasopharynx .....................................................................24B. Thyroid..............................................................................25

IV. Definition of Lymph Node Groups .........................................29

V. Conceptual Guidelines for Neck Dissection Classification .....33A. Radical Neck Dissection....................................................33B. Modified Radical Neck Dissection.....................................34C. Selective Neck Dissection..................................................35D. Extended Radical Neck Dissection.....................................37


10/30

8

I. INTRODUCTION

The tumor, node, metastasis (TNM) staging system allows cliniciansto categorize tumors of the head and neck region in a specific man-

ner to assist with the assessment of disease status, prognosis, andmanagement. All available clinical information may be used in stag-ing: physical exam, radiographic, intraoperative, and pathologicfindings, Other than histopathologic analysis, biomarkers and molec-ular studies are not yet included in the staging of head and neck can-cers.

Three categories comprise the system: Tthe characteristics of thetumor at the primary site (this may be based on size, location, orboth); Nthe degree of regional lymph node involvement; and Mthe absence or presence of distant metastases. The specific TNM sta-tus of each patient is then tabulated to give a numerical status ofStage I, II, III, or IV. Specific subdivisions may exist for each stageand may be denoted with an a, b, or c status. In general, early-stagedisease is denoted as Stage I or II disease, and advanced-stage dis-

ease as Stage III or IV disease. Of importance is that any positivemetastatic disease to the neck will classify the disease as advanced,except in select nasopharynx and thyroid cancers.

A. Upper Aerodigestive Tract Sites

The majority of tumors arising in the head and neck (other than non-melanoma skin cancers) arise from the squamous mucosa that lines

the upper aerodigestive tract (UADT) and are predominately squa-mous cell carcinomas. The UADT begins where the skin meets themucosa at the nasal vestibule and the vermillion borders of the lipsand continues to the junction of the cricoid cartilage and the cervicaltrachea and at the level of the cricoid where the hypopharynx meetsthe cervical esophagus. The UADT is organized into several majorsites that are subdivided to several anatomic subsites. The major sites

include (1) the oral cavity, (2) the oropharynx, (3) the hypopharynx,


11/30

9

(4) the larynx, (5), the nasopharynx, (6) and the nose and paranasalsinuses.

1. Oral Cavity

The oral cavity is a common site for squamous cell cancers of theUADT, probably because it is the first entry point for many carcino-gens. The anterior aspect of the oral cavity is the contact point of theskin with the vermilion of the lips extending posteriorly to the junc-tion of the hard and soft palates, and with the anterior tonsillar pillarsand the circumvallate papillae forming the posterior limits. Themajor subsites of the oral cavity are the lips, anterior tongue, floor of

mouth, buccal mucosa, upper and lower alveolar ridges, hard palate,and retromolar trigone. The trigone consists of the mucosa overlyingthe anterior aspect of the ascending ramus of the mandible. Tumorsof the oral cavity tend to spread regionally to lymph nodes of thesubmandibular region (Level I) and to the upper and middle jugularchain lymph nodes (Levels II and III).

Because of accessibility and the risk of involvement of bony struc-tures, treatment with radiotherapy can lead to radionecrosis of themandible or maxilla. Moreover, oral cavity squamous cell carcino-mas may be less sensitive to chemotherapy and radiation, relative tooropharyngeal or laryngeal cancers. Thus, primary treatment formost tumors is surgical. Positive surgical margins, multiple involvedlymph nodes, and/or extracapsular tumor extension call for consid-eration of postoperative chemoradiotherapy, to improve local dis-

ease control.

2. Oropharynx

This structure begins where the oral cavity ends at the junction ofthe hard and soft palates superiorly and the circumvallate papillae in-feriorly and extends from the level of the soft palate superiorly, whichseparates it from the nasopharynx and to the level of the hyoid bone

inferiorly, where the hypopharynx begins. The subsites of the


12/30

10

oropharynx are the tonsil, base of tongue, soft palate, and pharyngealwalls. Cancers of the oropharynx often metastasize to upper andmiddle jugular chain lymph nodes (Levels II and III), but can alsospread to retropharyngeal lymph nodes, which distinguishes them

from oral cavity tumors and must be considered when treatingoropharyngeal cancers. Tumors in this site are generally treated withradiotherapy, as a single modality for T 1/2 or N 0/1 stages. Increas-ingly, some of these cancers are associated with human papillomavirus 16 infection, especially in nonsmokers. However, for patientswith more advanced disease, T 3/4 or N 2 b/c/3 staging, chemora-diotherapy most often with a concomitant approach has becomestandard. Cisplatin, administered during weeks 1, 4, and 7 has mostoften been studied and may be considered a standard. Nonetheless,other regimens, carboplatin, taxanes, and drug combinations, suchas cisplatin or carboplatin with fluorouracil, are also reported. In-duction chemotherapy before radiotherapy (or chemoradiotherapy)remains an investigational strategy.

3. Hypopharynx

The hypopharynx has its superior limit at the hyoid bone, where it iscontiguous with the oropharynx and it extends inferiorly to thecricopharyngeus muscle, where it meets the cervical esophagus. Themajor subsites of the hypopharynx are the pyriform sinuses, the post-cricoid region, and the pharyngeal walls. Tumors often present here atadvanced stages and can be difficult to cure, and because of their lo-cation can impact swallowing and speech function adversely. Spread

to the upper, middle, and lower jugular lymph nodes (Levels IIIV) andthe retropharyngeal nodes is common in these cancers. Two other hall-marks of hypopharyngeal cancers are submucosal spread and skipareas of spread. Surgery had been the mainstay of primary treatment forhypopharyngeal cancers for many years, but increasingly radiotherapyand chemoradiotherapy are used to treat cancers in this location withsuccess.


13/30

11

4. Larynx

The larynx is the most complex of the mucosal lined structures ofthe UADT. Its important roles in speech, swallowing, and airwayprotection make the treatment considerations of cancers of this struc-ture varied and controversial. The larynx is bordered by the orophar-ynx superiorly, the trachea inferiorly, and the hypopharynx laterallyand posteriorly. The larynx is comprised of a cartilaginous frame-work, and is subdivided vertically by the vocal cords into the supra-glottic, glottic, and subglottic subsites. The supraglottic larynxincludes the epiglottis, which has both lingual and laryngeal sur-faces, the false vocal cords, the arytenoids cartilages, and the

aryepiglottic folds. Anterior to the supraglottis is the pre-epiglotticspace. This is a complex space with a rich lymphatic network thatcontributes to the early and bilateral spread of tumors that arise fromsupraglottic structures to upper, middle, and lower jugular chainlymph nodes.

The glottic larynx describes the true vocal cords, and where theycome together anteriorly at the anterior commissure, as well aswhere they meet the mobile laryngeal cartilages at the posteriorcommissure. The glottic larynx extends from the ventricle to 1 cmbelow the level of the true cords. The vocal cords are lined with strat-ified squamous epithelia, which contrasts with the pseudostratifiedciliated respiratory mucosa lining the remainder of the larynx. Glotticlaryngeal cancers tend to metastasize unilaterally and spread region-ally less commonly than supraglottic tumors do. Between the thyroid

cartilage and the vocal cord lies the paraglottic space, which is con-tinuous with the pre-epiglottic space. This serves as a pathway forsubmucosal spread of tumors from the glottis to the supraglottis, orvice versa, which is known as transglottic spread. The subglottic lar-ynx starts 1 cm below the vocal folds and continues to the inferioraspect of the cricoid cartilage. While it is rare for tumors to arise ini-tially in the subglottis, tumors arising in the supraglottic or glotticlarynx commonly spread in a transglottic fashion to involve the


14/30

12

subglottic larynx. Subglottic tumors tend to metastasize to paratra-cheal (Level VI) as well as middle or lower jugular lymph (Levels IIIand IV) node groups.

Treatment of laryngeal cancers varies widely from center to center,and for early-stage lesions radiotherapy or transoral endoscopic ex-cision are the most common treatment options. Both yield excellenttumor control, but proponents of each modality often disagree onthe functional sequelae of the two types of treatment. However, goodlong-term functional data are lacking. Treatment of more advancedtumors can be even more controversial, but while total laryngectomywas long held as the gold standard for treating T3 and T4 larynx can-cers, chemoradiotherapy has been shown to be quite effective inachieving local regional control, survival, and organ preservation.Concomitant chemoradiotherapy may be most appropriate for T3primary lesions. Treatment of both sides of the neck must be takeninto consideration when treating supra- and subglottic tumors, andunilateral neck treatment is considered for patients with advancedglottic tumors.

5. Nasopharynx

The nasopharynx is a cuboidal structure bounded anteriorly by thechoanae at the back of the nose where pseudostratified ciliatedcolumnar cells are found. The roof and posterior walls of the na-sopharynx are made up of the sphenoid bone and the upper cervicalvertebrae, covered with a stratified squamous epithelial lining. Infe-

riorly, at the level of the soft palate, the nasopharynx meets the su-perior oropharynx. The opening of the Eustachian tube is found atthe posterior-superior aspect of either lateral nasopharyngeal wall;therefore, impingement of this opening by a nasopharyngeal tumorcan lead to Eustachian dysfunction manifested by a middle-ear effu-sion and hearing loss. Thus, all adult patients with an unexplainedunilateral middle-ear effusion, particularly in areas where nasopha-ryngeal carcinoma is endemic (such as southern China, northern


15/30

13

Africa, and Greenland), should have their nasopharynx examined.The adenoids, consisting of mucosa-covered lymphoid tissue, arefound posteriorly and superiorly in the nasopharynx and are moreprominent in children than adults.

While minor salivary tumors can occur in the nasopharynx, most na-sopharyngeal cancers are derived from the mucosal lining and fitinto one of the three histologic subtypes described by the WorldHealth Organization (WHO). WHO Type I nasopharyngeal carci-noma (NPC) is keratinizing squamous carcinoma, and WHO Type IIis nonkeratinizing squamous cell carcinoma. WHO Type III is an un-differentiated tumor, also known as lymphoepithelioma. The Epstein-Barr virus is thought to play a pathogenic role in the development ofType II and III tumors. Nasopharyngeal carcinoma may also metas-tasize to retropharyngeal and parapharyngeal lymph nodes, as wellas lymph nodes along the upper, lower, and middle jugular (LevelsIIIV) chains and the posterior triangle of the neck (Level V). Early-stage NPC is most often treated with radiotherapy alone, and in moreadvanced cases, T 3/4 N +/ concomitant chemotherapy is being in-

creasingly utilized. Surgery is rarely used in salvage situations at theprimary site or neck.

6. Nasal Cavity and Paranasal Sinuses

The paranasal sinuses consist of the paired maxillary sinuses, the su-perior frontal sinuses, the bilateral ethmoid system, and the centralspenoids. This region includes the lining of the nasal cavity (medial

maxillary walls) as well as the nasal septum. The majority ofsinonasal carcinomas arise in the maxillary sinuses and are mostcommonly squamous cell carcinomas, although adenocarcinomasare described, especially in woodworkers. Because of inherent boneinvolvement, initial treatment is usually surgical, with considerationfor adjuvant radiation therapy based upon stage and pathologic find-ings. Reconstruction and rehabilitation, especially in cases with or-bital involvement, may be prosthetic or tissue based. Sinonasal


16/30

14

carcinomas of the anterior skull base include a variety of pathologies.Standard treatment is multidisciplinary, including craniofacial surgi-cal intervention with adjuvant radiation and chemotherapy.

B. Radiation Therapy and ChemotherapyExternal beam radiation therapy (RT) alone or in conjunction withchemotherapy has a well-established role in the treatment of headand neck cancer as definitive therapy or as adjuvant to primary sur-gical treatment. The last two decades have seen tremendous techno-logical developments in targeting and delivery of RT in a complextreatment site such as the head and neck. Three-dimensional (3-D)

conformal RT marked a significant improvement over the conven-tional two-dimensional 3-field setup in better delineation of tumorvolume and nodal volume. This improvement allows limited dosingto normal tissue, while adequately treating the tumor. However, 3-D conformal planning does not always result in optimal shielding ofcritical normal tissues (e.g., salivary glands and visual apparatus),due to current beam constraints.

Intensity-modulated radiation therapy (IMRT) allows for better spar-ing of such critical normal tissues by modulating the radiation beamin multiple small beamlets, while at the same time adequately cov-ering the tumor volume. With the advent of IMRT, it is also very im-portant for the clinician to be acutely aware of radiologic anatomy(levels of nodal disease, pathways of loco-regional spread of tumor,and delineation of postoperative tumor bed), while utilizing com-

puted tomography, scan magnetic resonance imaging, and positronemission tomography scan for treatment planning.

Preoperative clinical and radiologic evaluation of disease is ex-tremely important for postoperative radiotherapy planning, as tissueplanes may be obscured after surgery. Such evaluation is also valu-able in determining whether ipsilateral or bilateral neck diseaseneeds to be addressed based on tumor location, extent, and size; ini-


17/30

15

tial nodal presentation; and likelihood of contralateral nodal involve-ment. Certain primary tumor sites have a high risk of retropharyngealnodal involvement (nasopharynx, piriform sinus, and tongue base),and these nodal groups should be covered in RT target volumes for

these tumors. Approximately 20% of anterior tongue and floor ofmouth cancers may have skip nodal metastasis to Level IV nodal re-gion, and should be included in RT volumes.

Important considerations in RT planning following surgical resectioninclude a thorough evaluation of the surgical pathology report withrespect to resection margins, extension to soft tissue/bone, and per-ineural or lympho-vascular invasion at the primary site and size;extra-capsular extension (ECE); and the number and level of nodalinvolvement. Postoperative patients with ECE are at high risk forloco-regional recurrence. Careful adjuvant treatment planning in-cludes consideration of radiation dose (6066 Gy), addition of con-current chemotherapy (RTOG 95-01), extension of the RT clinicaltarget volume to include overlying skin, and elective irradiation ofcontralateral neck nodes. The clinical target volume in radiation ther-

apy of a clinically or pathologically involved neck typically extendsup to the skull base to treat the highest neck nodes. In the contralat-eral elective neck irradiation, the highest treated nodes are jugulo-digastric nodes.

Adjuvant RT should ideally begin within 46 weeks following pri-mary surgical resection and neck dissection, unless postoperativecomplications significantly delay wound healing. Delaying adjuvanttherapy has been shown to significantly decrease loco-regional con-trol.


18/30

16

II. AMERICAN JOINT COMMITTEE ON CANCER (AJCC)TUMOR STAGING BY SITE

A. Oral Cavity

Definition:The anterior border is the junction of the skin and vermil-ion border of the lip. The posterior border is formed by the junctionof the hard and soft palates superiorly, the circumvallate papillae in-feriorly, and the anterior tonsillar pillars laterally. The various siteswithin the oral cavity include the lip, gingival, hard palate, buccalmucosa, floor of mouth, anterior 2/3 of tongue, and retromolartrigone.

TX Primary tumor cannot be assessed.T0 There is no evidence of primary tumor.

Tis Carcinoma is in situ.

T1 Tumor is 2 cm or less in greatest dimension.

T2 Tumor is more than 2 cm but not greater than 4 cm ingreatest dimension.

T3 Tumor is more than 4 cm in greatest dimension.T4 (lip) Tumor invades through cortical bone, inferior alveolar

nerve, floor of mouth, or skin of facei.e., chin or nose.

T4a (oral Tumor invades adjacent structures (e.g., throughcavity) cortical bone, into deep [extrinsic] muscle of tongue

[genioglossus, hypoglossus, palataglossus, and sty-loglossus], maxillary sinus, skin of face).

T4b Tumor invades masticator space, pterygoid plates, orskull base and/or encases the internal carotid artery.

Note:Superficial erosion alone of bone/tooth socket by gingival pri-mary is not sufficient to classify as T4.

B. Oropharynx

Definition:The oropharynx includes the base of the tongue, the in-ferior surface of the soft palate and uvula, the anterior and posterior


19/30

17

tonsillar pillars, the glossotonsillar sulci, the pharyngeal tonsils, andthe lateral and posterior pharyngeal walls.

T1 Tumor is 2 cm or less in greatest dimension.

T2 Tumor is more than 2 cm but not more than 4 cm in greatestdimension.

T3 Tumor is more than 4 cm in greatest dimension.

T4a Tumor invades the larynx, deep/extrinsic muscle of the tongue,medial pterygoid, hard palate, or mandible.

T4b Tumor invades the lateral pterygoid muscle, pterygoid plates,lateral nasopharynx, or skull base or encases the carotid artery.

C. Larynx

Site Subsite

Supraglottis Suprahyoid epiglottisInfrahyoid epiglottisAryepiglottic folds (laryngeal aspect)

ArytenoidsVentricular bands (false cords)

Glottis True vocal cords, including anterior and posteriorcommisures, including the region 1 cm below theplane of the true vocal folds

Subglottis Region extending from 1 cm below the true vocalfolds to the cervical trachea

Primary Tumor (T)

TX Primary tumor cannot be assessed.

T0 There is no evidence of primary tumor.



20/30

18

Supraglottis

T1 Tumor is limited to one subsite of the supraglottis, with normalvocal cord mobility.

T2 Tumor invades mucosa of more than one adjacent subsite ofthe supraglottis or glottis or region outside the supraglottis (e.g.,mucosa of base of tongue, vallecula, medial wall of pyriformsinus), without fixation of the larynx.

T3 Tumor is limited to the larynx with vocal cord fixation and/orinvades any of the following: postcricoid area, pre-epiglottictissues, paraglottic space, and/or minor thyroid cartilage ero-sion (e.g., inner cortex).

T4a Tumor invades through the thyroid cartilage and/or invades tis-sues beyond the larynx (e.g., trachea, soft tissues of neck, in-cluding deep extrinsic muscle of the tongue, strap muscles,thyroid, or esophagus).

T4b Tumor invades prevertebral space, encases the carotid artery, orinvades mediastinal structures.

Glottis

T1 Tumor is limited to the vocal cords(s) (may involve anterior orposterior commissure), with normal mobility.

T1a Tumor is limited to one vocal cord.

T1b Tumor involves both vocal cords.

T2 Tumor extends to the supraglottis and/or subglottis, and/or with

impaired vocal cord mobility.T3 Tumor is limited to the larynx with vocal cord fixation and/or

invades paraglottic space, and or minor thyroid cartilage ero-sion (e.g., inner cortex).

T4a Tumor invades through the thyroid cartilage and/or invades tis-sues beyond the larynx (e.g., trachea, soft tissues of the neck,including deep extrinsic muscle of the tongue, strap muscles,

thyroid, or esophagus).


21/30

19


Subglottis

T1 Tumor is limited to the subglottis.

T2 Tumor extends to the vocal cord(s), with normal or impairedmobility.

T3 Tumor is limited to the larynx, with vocal cord fixation.

T4a Tumor invades cricoid or thyroid cartilage and/or invades tis-sues beyond the larynx (e.g., trachea, soft tissues of neck, in-

cluding deep extrinsic muscles of the tongue, strap muscles,thyroid, or esophagus).


D. Hypopharynx

Definition:The hypopharynx includes the pyriform sinuses, the lat-

eral and posterior hypopharyngeal walls, and the postcricoid region.

T1 Tumor is limited to one subsite of the hypopharynx and 2 cmor less in greatest dimension.

T2 Tumor invades more than one subsite of the hypopharynx or anadjacent site, or measures more than 2 cm but not more than4 cm in greatest dimension without fixation of the hemilarynx.

T3 Tumor is more than 4 cm in greatest dimension or with fixationof the hemilarynx.

T4a Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroidgland, esophagus, or central compartment soft tissue.

T4b Tumor invades prevertebral fascia, encases the carotid artery, orinvolves mediastinal structures.


22/30

20

E. Nasal Cavity and Paranasal Sinuses

Definition: The paranasal sinuses include the ethmoid, maxillary,sphenoid, and frontal sinuses.

TX Primary tumor cannot be assessed.T0 There is no evidence of primary tumor.


Maxillary Sinus

Definition:The maxillary sinus is a pyramid-shaped cavity withinthe maxillary bone. The medial border is the lateral nasal wall. Su-periorly, the sinus abuts the orbital floor and contains the infraorbitalcanal. The posterolateral wall is anterior to the infratemporal fossaand pterygopalatine fossa. The anterior wall is posterior to the facialskin and soft tissue. The floor of the maxillary antrum extends belowthe nasal cavity floor and is in close proximity to the hard palate andmaxillary tooth roots.

T1 Tumor is limited to the maxillary sinus mucosa, with no erosion

or destruction of bone.T2 Tumor is causing bone erosion or destruction, including exten-

sion into the hard palate and/or middle nasal meatus, exceptextension to the posterior wall of the maxillary sinus and ptery-goid plates.

T3 Tumor invades any of the following: bone of the posterior wallof the maxillary sinus, subcutaneous tissues, floor, or medial

wall of the orbit, pterygoid fossa, or ethmoid sinuses.T4a Tumor invades anterior orbital contents, skin of cheek, ptery-

goid plates, infratemporal fossa, cribriform plate, sphenoid orfrontal sinuses.

T4b Tumor invades any of the following: orbital apex, dura, brain,middle cranial fossa, cranial nerves other than maxillary divi-sion of trigeminal nerve (V2), nasopharynx, or clivus.


23/30

21

Nasal Cavity and Ethmoid Sinus

Definition:The nasal cavity includes the nasal antrum and the olfac-tory region. The subsites within the nasal cavity include the septum;superior, middle, and inferior turbinates; and olfactory region of thecribriform plate. The ethmoid sinus is made up of several thin-walledair cells. Laterally, the ethmoid sinus is bound by a thin bone calledthe lamina papyracea, which separates it from the medial orbit. Theposterior border of the ethmoid sinus is close to the optic canal. Theanterosuperior border or roof of the ethmoid is formed by the foveaethmoidalis, which separates it from the anterior cranial fossa. Theperpendicular plate of the ethmoid bone separates the ethmoid cav-

ity into left and right sides.T1 Tumor is confined to the ethmoid sinus with or without bone

erosion.

T2 Tumor invades two subsites in a single region or extends to in-volve an adjacent region within the nasoethmoidal complex,with or without bony invasion.

T3 Tumor extends to invade the medial wall or floor of the orbit,

maxillary sinus, palate, or cribriform plate.T4a Tumor invades any of the following: anterior orbital contents,

skin of nose or cheek, minimal extension to anterior cranialfossa, pterygoid plates, sphenoid or frontal sinuses.

T4b Tumor invades any of the following: orbital apex, dura, brain,middle cranial fossa, cranial nerves other than (V2), nasophar-ynx, or clivus.

F. Salivary Glands

Definition:The salivary glands include the parotid, submandibular,sublingual, and minor salivary glands.

T1 Tumor is 2 cm or less without extraparenchymal extension.

T2 Tumor is greater than 2 cm but not more than 4 cm without ex-

traparenchymal extension.


24/30

22

T3 Tumor is more than 4 cm and/or extraparenchymal extension.

T4a Tumor invades the skin, mandible, ear canal, and/or facialnerve.

T4b Tumor invades the skull base and/or pterygoid plates and/orencases the carotid artery.

G. Neck Staging Under the TNM Staging System for Headand Neck Tumors (excluding nasopharynx and thyroid)

NX Regional lymph nodes cannot be assessed.

N0 There is no regional nodes metastasis.

N1 Metastasis is in a single ipsilateral lymph node, 3 cm or less ingreatest dimension.

N2 Metastasis is in a single ipsilateral lymph node, more than 3cm but not more than 6 cm in greatest dimension; or metastasisis in multiple ipsilateral lymph nodes, none more that 6 cm ingreatest dimension; or metastasis is in bilateral or contralaterallymph nodes, none greater than 6 cm in greatest dimension.

N2a Metastasis is in a single ipsilateral lymph node, more than 3cm but not more than 6 cm in greatest dimension.

N2b Metastasis is in multiple ipsilateral lymph nodes, none morethat 6 cm in greatest dimension.

N2c Metastasis is in bilateral or contralateral lymph nodes, nonemore than 6 cm in greatest dimension.

N3 Metastasis is in a lymph node more than 6 cm in greatest di-

mension.

U, L A designation of U or L may be given in addition to indi-cate the level of metastasis above the lower border of thecricoid cartilage (U) or below the lower border of the cricoidcartilage (L).


25/30

23

Distant Metastasis (M)

MX Distant metastasis cannot be assessed.

M0 There is no distant metastasis.

M1 There is distant metastasis.

H. TNM Staging for the Larynx, Oropharynx, Hypopharynx,Oral Cavity, Salivary Glands, and Paranasal Sinuses

Stage Grouping

Stage 0 Tis N0 M0

Stage I T1 N0 M0Stage II T2 N0 M0Stage III T3 N0 M0

T1 N1 M0T2 N1 M0T3 N1 M0

Stage IVA T4a N0 M0T4a N1 M0T1 N2 M0T2 N2 M0T3 N2 M0T4a N2 M0

Stage IVB T4b Any N M0Any T N3 M0

Stage IVC Any T Amy N M1

Clinical Stage Grouping by T and N Status

T1 T2 T3 T4a T4b N0 I II III IVa IVbN1 III III III IVa IVbN2 IVa IVa IVa IVa IVbN3 IVb IVb IVb IVb IVb


26/30

24

III. AJCC TUMOR STAGINGNASOPHARYNXAND THYROID

A. Nasopharynx

Definition:The nasopharynx includes the vault, the lateral walls, theposterior walls, and the superior surface of the soft palate.

T1 Tumor is confined to the nasopharynx.

T2 Tumor extends to soft tissues.

T2a Tumor extends to the oropharynx and/or nasal cavity, withoutparapharyngeal extension.

T2b Tumor extends into the parapharyngeal space.

T3 Tumor involves bony structures and/or paranasal sinuses.

T4 Tumor has intracranial extension and/or involves cranialnerves, infratemporal fossa, hypopharynx, orbit, or masticatorspace.

Regional Lymph Nodes(different from other head and neck sites)

N0 There is no regional lymph node metastasis.N1 Unilateral metastasis in lymph node(s) is 6 cm or less in greatest

dimension, above the supraclavicular fossa.

N2 Bilateral metastasis in lymph nodes is 6 cm or less in greatestdimension, above the supraclavicular fossa.

N3 Metastasis in lymph node(s) is greater than 6 cm and/or to thesupraclavicular fossa.

N3a Tumor is greater than 6 cm in dimension.

N3b Tumor extends to the supraclavicular fossa.


27/30

25

Stage Grouping(unique to site)

Stage 0 Tis N0 M0Stage I T1 N0 M0Stage IIA T2a N0 M0Stage IIB T1 N1 M0

T2 N1 M0T2a N1 M0T2b N0 M0T2b N1 M0

Stage III T1 N2 M0T2a N2 M0

T2b N2 M0T3 N0 M0T3 N1 M0T3 N2 M0

Stage IVA T4 N0 M0T4 N1 M0T4 N2 M0

Stage IVB Any T N3 M0Stage IVC Any T Any N M1

B. Thyroid

Definition:The thyroid is composed of a right and left lobe, with anisthmus connecting the two lobes.

Primary Tumor (T)TX Primary tumor cannot be assessed.

T0 There is no evidence of primary tumor.

T1 Tumor is 2 cm or less in greatest dimension and is limited to thethyroid.

T2 Tumor is more than 2 cm but not more than 4 cm in greatest di-mension, and is limited to the thyroid.


28/30

26

T3 Tumor is more than 4 cm in greatest dimension, and is limitedto the thyroid or any tumor with minimal extrathyroid exten-sion (e.g., extension to sternothyroid muscle or perithyroid softtissues).

T4a Tumor of any size extends beyond the thyroid capsule to in-vade subcutaneous soft tissues, larynx, trachea, esophagus, orrecurrent laryngeal nerve.

T4b Tumor invades prevertebral fascia or encases the carotid arteryor mediastinal vessels.

All anaplastic carcinomas are considered T4 tumors

T4a Intrathyroidal anaplastic carcinomasurgically resectable.

T4b Extrathyroidal anaplastic carcinomasurgically unresectable.

Regional Lymph Nodes (N)

Regional lymph nodes are the central compartment, lateral cervical,and upper mediastinal lymph nodes.NX Regional lymph nodes cannot be assessed.

N0 There is no regional lymph node metastasis.N1 There is regional lymph node metastasis.

N1a There is metastasis to Level VI (pretracheal, paratracheal, andprelaryngeal/Delphian lymph nodes).

N1b There is metastasis to unilateral, bilateral, or contralateral cer-vical or superior mediastinal lymph nodes.

Distant Metastasis (M)

MX Distant metastasis cannot be assessed.

M0 There is no distant metastasis.

M1 There is distant metastasis.


29/30

27

Stage Grouping

Separate stage groupings are recommended for papillary or follicular,medullary, and anaplastic (undifferentiated) carcinoma.

Papillary or Follicular(Younger than 45 years)Stage I Any T Any N M0Stage II Any T Any N M1

Papillary or Follicular(45 years and older)

Stage I T1 N0 M0Stage II T2 N0 M0Stage III T3 N0 M0

T1 N1a M0T2 N1a M0T3 N1a M0

Stage IVA T4a N0 M0T4a N1a M0T1 N1b M0T2 N1b M0T3 N1b M0T4a N1b M0


Stage IVC Any T Any N M1

Medullary CarcinomaStage I T1 N0 M0Stage II T2 N0 M0Stage III T3 N0 M0

T1 N1a M0T2 N1a M0T3 N1a M0


30/30

Stage IVA T4a N0 M0T4a N1a M0T1 N1b M0T2 N1b M0

T3 N1b M0T4a N1b M0


Stage IVC Any T Any N M1

Anaplastic Carcinoma(All anaplastic carcinomas are considered Stage IV)Stage IVA T4a Any N M0Stage IVB T4b Any N M0Stage IVC Any T Any N M1

Neck Dissection Part 1

Documents